-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on Iovance Biotherapeutics, Raises Price Target to $8

Benzinga·08/07/2026 15:01:54
Listen to the news
Citizens analyst Reni J. Benjamin maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Market Outperform and raises the price target from $5 to $8.